STAT1 and neoplasm: Combining anti-PD-L1 antibodies with ferroptosis inducers has shown significant efficacy in inhibiting tumor growth, attributed to the release of interferon-γ by cytotoxic T cells, which activates STAT1 and inhibits xCT expression, thereby promoting ferroptosis (258).